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Abstract 
  
At present, 94 breast cancer susceptibility loci have been discovered from genome-wide 
association studies (GWAS). The next step is to identify the causal risk variant, the target gene 
and to understand the underlying disease mechanism. Studies revealed that most of the variants 
discovered by GWAS are cis-acting regulatory. Cis-acting regulatory variants can be identified 
most efficiently by differential allelic expression (DAE) analysis. A DAE genome-wide mapping 
was done in normal breast tissue, which was cross-compared with GWAS breast cancer data. 19 
loci associated with risk and with evidence of cis-regulation were identified, including the 5q14.2 
locus that has one SNP associated with risk - rs7707921, and five SNPs displaying DAE across three 
genes: ATG10, RPS23 and ATP6AP1L. 
The aim of this thesis is to set out to map the regulatory variants responsible for the DAE 
signals in the 5q14.2 locus and to determine which one(s) is (are) associated with risk for breast 
cancer.  
We performed in silico analysis using data obtained through publically accessible 
databases, to identify candidate regulatory SNPs (rSNPs) that could be responsible for the DAE 
and determine if they may be associated with risk to breast cancer. Experimental in vitro analysis 
by EMSA and analysis of available ChIP-seq data was also conducted in order to investigate 
possible interactions between candidate rSNPs and transcription factors (TFs).  
In this study, three SNPs rs226198, rs6880209 and rs17247678 were identified as 
potential cis-acting regulators of ATG10, RPS23 and ATP6AP1L. Henceforth, we propose a risk 
model based on our findings: Binding of c-Myc and POL2 to the common allele of rs226198 and 
rs6880209 lead to over expression of RPS23 and under expression of ATG10, respectively, 
whereas, binding of STAT3 and c-FOS to rs17247678 lead to under expression of ATP6AP1L, 
increasing the risk for breast cancer.  
 
Keywords: breast cancer; genetic risk; cis-acting regulatory variants; differential allelic expression  
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Chapter 1: Introduction 
 
1.1 Cancer 
In the human body, new cells will grow and divide in order to replace old or damaged cells 
that will eventually die. However, when these new cells start to grow out of control, it can lead 
to serious illness or death. This abnormal cellular growth is called cancer. It can start anywhere 
within the human body then invade and spread to other parts of the body.  
In 2000, Hanahan et. al. suggested six key elements for cancer development.  These key 
elements, named “The Hallmarks of Cancer”, include activating invasion and metastasis, enabling 
replicative immortality, inducing angiogenesis, resisting cell death, sustaining proliferative 
signalling and evading growth suppressor1,2. Additional four hallmarks were added in 2011, these 
are avoiding immune destruction, tumour-promoting inflammation, deregulating cellular 
energetics and genome instability and mutation (Figure 1)2.  
 
Figure 1 :  Hallmarks of Cancer. Modified from Hanahan et. al., 2011. 
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Genomic instability is a major leading force for carcinogenesis3. In hereditary cancers, the 
establishment of genomic instability could be the launching pad, in which it facilitates the 
beginning of all the other hallmarks. Meanwhile for non-hereditary cancers, the deregulation of 
proliferation regulating genes could be the start-up reason. Subsequently, this leads to DNA 
damage and DNA replication stress, which then points to genomic instability and selective 
pressure for tumour suppressor p53 inactivation. Failure of the p53 function allows cell evasion 
from cell death and with genomic instability, it provides a fertile ground for additional mutations 
that lead to the start of the remaining hallmarks4. 
Cancer contributes amongst the leading number of morbidity and mortality worldwide, 
having 14.1 million new cases and 8.2 million deaths reported in GLOBOCAN 20125. In relation to 
these numbers, it is estimated that 24.4% of cancer incidence and 21.5% of cancer mortality 
occurs in Europe (Figure 2). 
 
 
Figure 2 : Estimated numbers of incidence and mortality cases by world regions, 2012. Ferlay et. al., 2015. 
 
In 2015, World Health Organisation (WHO) estimates that the number of new cases will 
rise by about 70% in the next 20 years. The most common cancer that occurs among men are 
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lung, prostate, colorectum, stomach and liver cancer. Meanwhile in women, the most common 
cancer occurrence are breast, colorectum, lung, cervix and stomach cancer5. 
 
 
1.2 Breast Cancer 
 
1.2.1 Epidemiology 
 As mentioned previously, breast cancer occurs most frequently amongst women, with 
25% overall of cancer cases in women worldwide. According to GLOBOCAN 2012, there were 
about 1.67 million cases of breast cancer and this contributed to about 11.9% of the total cancer 
cases worldwide5. Subsequently, this puts breast cancer as the 5th most deadly cancer with 
522,000 deaths per year, making up 6.4% of overall cancer deaths.  
In Europe, it is estimated that 464,200 new breast cancer cases arise per year, meanwhile 
131,300 cases leads to death. Incidence rates differ by 10.1% between the more developed 
regions with the less developed regions. However, mortality rates between these classes of 
regions differ by 39.7%. The reason for this difference is thought to be due to patients having 
better survival rates due to better access of medical treatment in the more developed regions5. 
 
 
1.2.2 Risk Factors 
There are many factors that can contribute to the development of breast cancer. Non-
inherited risk factors such as age, weight, usage of hormonal contraception, hormone 
replacement treatment, dietary and lifestyle, could lead to the development of breast cancer in 
women6,7. Meanwhile women with family history of breast cancer have higher risk of developing 
the disease, compared to women who do not have any family history8,9. This genetic risk is further 
evident by the high concordance of breast cancer cases among monozygotic twins, compared to 
dizygotic twins or siblings10.  
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1.2.3 Genetic Susceptibility  
 Genetic susceptibility is a complex matter due to variation at many different loci. The 
susceptibility alleles at these loci have different frequencies and impose different cancer risks10. 
These genetic variants can be categorised into three groups, high penetrance alleles, moderate 
penetrance alleles and low penetrance alleles (Figure 3). Penetrance refers to the relative risk of 
developing cancer, conferred by an allele with a given population frequency.  
 
  
Figure 3 : Characterisation of breast cancer genetic susceptibility. In y-axis, it refers to the relative risk meanwhile in x-axis it refers 
to the risk allele frequency. Ghoussaini et. al., 2013. 
 
i. High Penetrance Alleles 
High penetrance alleles confer a high risk of developing cancer, with > 50% of lifetime risk. 
However, these alleles are rare in the population. BRCA1 and BRCA2 germ line mutations are 
amongst the few high penetrance alleles that were discovered back in 1990’s. These tumour 
suppressor genes are involved in DNA repair and confer a 10 - 30 fold increase in risk of 
developing cancer in carriers, compare to non-carriers11. Few other high penetrance alleles have 
been identified, such as, mutations in TP53 and STK11/LKB110.  
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ii. Moderate Penetrance Alleles 
Moderate penetrance alleles confer a moderate risk of developing cancer, with ≥ 20% of 
lifetime risk. Alleles that have been identified and classified into this group include mutations and 
polymorphisms in genes ATM, CHEK2, PALB2, BRIP1, PTEN and CDH1. These alleles confer a 2 - 8 
fold increase in risk to breast cancer10. 
 
iii. Low Penetrance Alleles 
Low penetrance alleles, were more recently identified through genome-wide associations 
studies, and confer a low risk of developing cancer, normally with 10 - 20% of lifetime risk. 
However, these alleles are common in the population with minor allele frequencies of > 5%, and 
are associated with a modest to low increase in breast cancer risk (< 1.5 fold)10. 
 
 
1.3 Genome-Wide Association Study  
Common low penetrance alleles are generally identified by case-control association 
studies such as genome-wide association studies (GWAS). GWAS functions by examining and 
comparing common DNA sequence variations in a large set of unrelated cases and controls in 
order to associate differences in allele frequencies at a polymorphic marker, with the trait of 
interest. However, this study model must be well-matched to avoid population stratification, as 
unmatched cases and controls study could lead to bias results, due to differences in race or 
ethnicity of those with and without the disease of interest.  
The genetic variations in GWASes are generally focused on single nucleotide 
polymorphisms (SNPs) and often these GWAS associated SNPs are located outside of genes in 
non-coding regions. So far, GWASes were able to identify hundreds of cancer susceptibility loci 
and currently there are 94 loci associated with breast cancer, which altogether explain ~ 16% of 
familial risk of this disease12. 
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Even though GWASes have enabled the association between genetic variations and risk 
for diseases, they were unable to precisely identify the association exact target. Therefore the 
biggest post-GWAS challenges are to (1) identify the causal variants and (2) the genes that are 
linked to these associations. Afterwards, further studies need to be done in order to understand 
the functional consequences of these causal variants and to correctly define the mechanism by 
which these genetic variations and affiliated genes act.  
 
 
1.4 Single Nucleotide Polymorphism 
There are millions of genetic variations with a minor allele frequency (MAF) of > 1% in the 
population. MAF (minor allele frequency) refers to the frequency at which the least common 
allele occurs in the population. These variations contribute to most of the human phenotypes, 
including complex physical traits or disease traits13,14. Common polymorphisms include tandemly 
repeated segments like the minisatellites with 0.1 – 20 kilobase (1,000 nucleotides), and 
microsatellites with 2 – 100 nucleotides, large copy number variants with 1 kilobase to several 
megabases, small segmental deletions/insertions/duplications and single nucleotide 
polymorphisms (SNPs)14.  
SNPs are DNA sequence variations that are caused by the difference of a single nucleotide. 
This type of variation contributes to about ~ 90% of human genetic variations and occurs in 
approximately every 500 - 1000 base pairs throughout the human genome15. SNPs may occur in 
coding or non-coding regions of genes. SNPs in coding regions can lead to changes in structure 
and biological properties of the encoded protein. Meanwhile, SNPs in non-coding regions may 
affect gene expression levels in an allele-specific manner, for example MAPK1, FGFR2, LSP1 and 
TNRC19 genes 13,15–21.  
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1.5 Cis-Acting Regulatory Elements 
 Gene expression is influenced by environmental variation, epigenetic modifications and 
genetic regulatory elements. One type of genetic regulatory elements is the cis-acting regulatory 
elements, which are regions of non-coding DNA that regulates the expression of gene on the 
same chromosome and are often located in close proximity to the regulated gene22. Cis-acting 
regulatory elements are considered to involve regulatory elements such as promoters and 
enhancers, as well as to be located in intronic regions, upstream of the gene, or hundreds of 
kilobases away23. 
As previously mention, an example of cis-acting regulatory elements are enhancers that 
works by binding to activator proteins that trigger DNA bending. Afterwards, these activators 
interact with co-activators to stimulate chromatin remodelling and histone modification. The 
activators then bind to mediators, triggering the assembly of RNA polymerase and general 
transcription factors at the promoter site. Finally, transcription begins (Figure 4).  
 
Figure 4 : Mechanism of Cis-Acting Regulated Gene Expression. Pearson Education Inc., 2012. 
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Cis-acting regulatory variants causes unequal levels of transcription as it favours a specific 
allele of the gene. This particular allele may contain a specific variant in a proximal promoter that 
may prevent transcription factor binding, altering the expression of the allelic transcript or vice 
versa (Figure 5.a). Another possible mechanism could be that a specific variant in a distal 
enhancer site may prevent combinatorial binding and affect transcriptional levels or vice versa 
(Figure 5.b).  
 
 
 
Figure 5 : Differential allelic expression in heterozygous through cis-acting regulatory. SNP in a promoter (a) or enhancer (b) may 
alter the binding affinity of transcription factors and this affects the level of expression of the alleles shown here as the black and 
white dots.  Modified from Jones et. al., 2011. 
Cis-acting regulatory variants can be identified by two different approaches: expression 
quantitative trait loci (eQTL) and differential allelic expression (DAE). eQTL seeks for association 
of variations in gene expression between different groups of genotypes. Meanwhile DAE 
compares the levels of the two transcribed alleles in an individual who is heterozygous for a 
transcribed SNP (tSNP)13,22,24. 
Several studies done by my research group and others, have shown that most of the 
variants identified by GWAS for multiple type of cancers are cis-acting regulatory12,18,20,25,26. 
Therefore, we hypothesise that the remaining risk associated variants identified from GWAS 
loci outside of genes are likely to be cis-acting regulatory, as well.  
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1.6 Differential Allelic Expression 
DAE identifies the difference of expression between two alleles of a gene. This is done by 
comparing the relative expression of the two transcribed alleles in a gene from the same 
heterozygous sample24. In the previous work of my supervisor, Professor Ana Teresa Maia and 
her colleagues, they have performed a DAE scan of the entire genome in normal breast tissue 
samples using microarrays and obtained a whole genome map of cis-acting regulatory SNPs in 
breast tissue (Figure 6). From this study, it was able to identify 7011 (21%) SNPs and 4258 (26%) 
genes that showed DAE. 
 
Figure 6 : Genome wide differential allelic expression in breast tissue. Maia. et. al., unpublished. 
 
DAE distribution patterns from the DAE map done by Maia et. al. were consistent with 
the scenarios presented by Xiao et. al (Figure 7)22. These scenarios are attributed to the different 
levels of linkage disequilibrium (LD) with the base measurement of r2 and D’ between the 
transcribed SNP (tSNP) and the regulatory SNP (rSNP). LD is the none random correlations among 
neighbouring alleles, indicating haplotypes inherited from single, ancestral chromosomes27.  
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In Scenario 1, the tSNP is in complete LD with the rSNP (r2=1) and all heterozygotes show 
DAE. This occurs because there is no recombination between tSNP and rSNP. Hence all 
heterozygous individuals with tSNP will also be heterozygous for rSNP. Furthermore, only two 
haplotypes exist in the population and the distribution of DAE can be seen as unidirectional for 
this scenario (Figure 7.a)22. 
In Scenario 2, the tSNP is in strong but not complete LD with the rSNP (r2<1, D’=1). In this 
aspect, heterozygous individuals with tSNP might be heterozygous or homozygous for the rSNP 
alleles. Therefore three possible haplotypes exist in the population (Figure 7.b)22. 
In Scenario 3, the tSNP and rSNP are in low LD with r2 and D’<1 hence four haplotypes 
exist in the population. DAE distribution in this scenario can be seen to be centred around 0 as 
both of the alleles are equally expressed (Figure 7.c)22. 
 
 
 
 
 
 
 
 
Figure 7: DAE Scenarios for different LD measurements between tSNP and rSNP. Xiao et. al., 2011. 
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1.7 Preliminary Data 
As to date, 94 loci associated with breast cancer susceptibility have been identified and 
for our group project, we used these GWAS SNPs information and overlapped it with the DAE 
map by Maia et. al.. (Overlapping data from GWAS SNPs and DAE map was done by another 
member of the research group, Dr Joana Xavier.) We looked for GWAS and DAE SNPs that were 
within ± 250 kilobases with each other and had pairwise LD scores of r2 > 0.6. Nineteen loci, with 
both GWAS associated SNPs and tSNPs displaying DAE, were identified. 
Interestingly, the locus 5q14.2, had five tSNPs displaying DAE, three of them in LD with 
the GWAS SNP rs7707921, which was discovered through meta-analysis performed for 52 
GWASes by Michailidou et. al. in 201512. 
The tSNPs involve are: rs10068160, rs10044824 and rs7733620, located at the gene 
ATG10; rs150934 located at the gene ATP6AP1L and rs226202 located at the gene RPS23. All 
tSNPs showed different LD scores with the GWAS SNP (rs7707921) and have uni-directional 
distribution similar to Xiao et. al. scenario 2, suggesting a strong but incomplete LD, between the 
regulatory SNP (rSNP) and the transcribed SNP (tSNP) (Figure 8). This distribution also indicated 
us that the samples that display DAE should be heterozygous for the rSNP and the samples that 
do not display DAE should be homozygous for the rSNP. 
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Figure 8 :  Five tSNPs with association with GWAS SNP rs7707921. In x-axis it indicate the heterozygous genotype and the y-axis 
indicates the normalised DAE ratio obtained. Dotted lines delimit the cut-off of preferential allelic expression ratio [Log 2 (1.5) = 
0.584]. 
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We hypothesise that the causal variant behind GWAS signal in, rs7707921, is cis-
regulatory and the DAE map can help to identify the causal regulatory variant as described in 
Figure 9.  We will use DAE information in order to identify the possible regulatory and risk-causing 
SNP(s) and then will functionally analyse it. In conclusion, we believe that DAE can be a strong 
tool to help prioritise GWAS data and to identify causal risk variant(s) and target gene(s) in cancer 
studies.   
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Figure 9 : Association between GWAS SNP, rs7707921 and the correlated five tSNPs from Maia et. al. DAE map. 
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Chapter 2: Aims 
 
The aims of this study are: 
 
1. To identify candidate cis-acting regulatory SNPs that may be responsible for the 
association identified at the GWAS meta-analysis SNP: rs7707921. This will be performed 
by integrating information from breast cancer risk with the DAE in the tSNPs: rs10068160, 
rs150934, rs10044824, rs226202 and rs7733620. 
2. To functionally analyse the regulatory potential of the candidate SNPs identified. 
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Chapter 3: Material and Method 
 
3.1 Study Samples 
 In this study, a total number of 290 samples were used. Eighty four samples were from 
normal breast tissue extracted from women who had undergone reduction mastectomy for 
reasons not related to cancer. These normal breast tissues were collected at Addenbrooke’s 
Hospital, Cambridge, United Kingdom. An additional 150 and 56 human B cell samples were 
extracted from anonymous healthy blood donors and cancer patients, respectively. These 
samples were collected in the Blood Centre at Addenbrooke’s Hospital with the approval of 
Addenbrooke’s Hospital Local Research Ethics Committee (REC Reference 04/Q0108/21 and 
06/Q0108/221). 
 DNA extraction were obtained from all samples using conventional SDS/Proteinase 
K/Phenol method meanwhile total RNA were extracted using TRIzol® method. All extraction 
procedures were done at University of Cambridge and the extracted RNA used for DAE analysis. 
 
 
3.2 In Silico Annotation of Variants Functional Information 
A computational approach was taken in order to identify regulatory SNP associated with 
breast cancer susceptibility in the 5q14.2 locus. Candidate regulatory SNPs with LD r2 ≥ 0.4 with 
rs7707921, were retrieved from HaploReg V3 database, (http://www.broadinstitute.org 
/mammals/haploreg/haploreg_v3.php). 
HaploReg is a bioinformatics tool used to explore annotations of non-coding genome at 
variants on haplotype blocks, such as candidate regulatory SNPs at disease associated loci. Using 
linkage disequilibrium information from the 1000 Genomes Project, it allows for the visualisation 
of linked SNPs and small indels along with their predicted chromatin state, their sequence 
conservation across mammals and their effect on regulatory motifs28. The effect of SNP on 
regulatory motifs was constructed from Position Weight Matrix (PWM) and scored based on 
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genomic sequences. PWM is a representation of the DNA binding preferences of transcription 
factors, used in computational molecular biology and regulatory genomics29. 
Additional functional information was obtained from the following database in order to 
shortlist candidate regulatory SNPs: the RegulomeDB database, (http://regulomedb.org/), is a 
database that annotates SNPs with known and predicted regulatory elements in the intergenic 
regions of human genome. Known and predicted regulatory DNA elements include regions of 
DNase I hypersensitivity, binding sites of transcription factors and promoter regions that have 
been biochemically characterised to regulate transcription. The database source include public 
datasets such as GEO, ENCODE project, Roadmap and published literature30. 
GEO (Gene Expression Omnibus) is a public repository that archives and freely distributes 
microarray, next-generation sequencing and other forms of high-throughput functional genomics 
data submitted by the research community31,32. ENCODE (Encyclopedia of DNA Elements) is a 
research project that aims to identify and characterise functional elements in the human 
genome, which can be accessed through public databases33. Roadmap is a database by The NIH 
Roadmap Epigenomics Mapping Consortium that produce a public resource of epigenomic map 
for stem cells and primary ex vivo tissues, selected to represent the normal counterparts of 
tissues and organ systems frequently involved in human disease34.  
RegulomeDB categorises SNPs with functional evidence according to a scoring scheme. 
SNPs with a score of 1 are likely to affect binding and are linked to expression of a gene target 
while SNPS with score of 2 are likely to affect binding and score 3 are less likely to affect binding. 
Lastly, SNPs with scores from 4 to 6 have minimal binding evidence. Scoring of a to f indicates the 
decrease of functional evidence in a SNP (Annex 1).         
The Human Protein Atlas database, (http://www.proteinatlas.org/), provides information 
on protein expression profiles from normal tissues, cancer tissues, cell lines, subcellular 
localisation and transcript expression levels35.  
Regulatory landscape for the candidate regulatory SNPs were generated on UCSC 
Genome Bioinformatics (http://genome-euro.ucsc.edu/index.html) using UCSC Genome Browser 
on Human Feb. 2009 (GRCH37/hg19) Assembly.  This online genome browser hosted by 
University of California, Santa Cruz (UCSC) is an interactive website that contains several 
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functional data such as histone modifications, DNAse I hypersensitivity sites, transcription factor 
ChIP-seq and chromatin state segmentation36. Histone modifications regulate chromatin 
structure and function by processes such as methylation and acetylation. These types of 
modification are markers for regulatory elements such as enhancers and promoters37.  
In vivo ChIP-seq data were retrieved from Broad-Novartis Cancer Cell Line Encyclopedia 
(CCLE) database38, (http://www.broadinstitute.org/ccle/home/54591/), using the database 
Integrative Genomics Viewer (IGV) version 2.53 analysis tool39,40. CCLE provides public access to 
genomic data, analysis and visualisation for about 1000 cell lines where as IGV is a high 
performance integrated visualisation of copy number, gene expression, phenotype and other 
genomic data. Meanwhile ChIP-seq (Chromatin immunoprecipitation sequencing) is a method 
used to analyse protein interaction with DNA. It combines chromatin immunoprecipitation with 
DNA sequencing to identify the binding sites of DNA-associated proteins.  
 
 
3.3 DAE Mapping Analysis 
A DAE mapping analysis was performed by plotting the distribution between DAE ratios 
against the candidate rSNPs genotypes groups (homozygous or heterozygous). A Welch’s t-test 
(unequal variances t-test) was applied to test the equality of DAE means between the 
homozygous and heterozygous group of samples for each candidate rSNP. The rSNPs genotypes 
used were retrieved from the previous DAE map study microarrays, as well as imputed 
(performed by Dr Joana Xavier). Genotype imputation is a process of predicting genotypes that 
are not directly assayed in individual samples. It is done by having a reference panel of haplotypes 
at a dense set of SNPs genotyped and a study sample of individuals that have been genotyped at 
a subset of these SNPs. This approach allows to predict the genotypes at the SNPs that are not 
directly genotyped in the study sample41. DAE mapping analysis was done in order to see if the 
candidate rSNPs could explain the DAE distribution in each tSNP.  
 
 
Erasmus Mundus Master in 
Quality in Analytical Laboratories 
18 
 
3.4 Genotyping 
 We did not have genotype information for rs2407153 and rs226198, therefore primers 
for both candidate SNPs (Annex 2) were designed for the purpose of genotyping study samples 
using polymerase chain reaction (PCR) method followed by Sanger sequencing. For both 
rs2407153 and rs226198 rSNPs, 4 ng of genomic DNA in final volume of 20 µL of PCR reaction 
constituted by KAPA 2G Robust Kit (Kapa Biosystems) and KAPA 2G Fast ReadyMix PCR Kit (Kapa 
Biosystems) master mix, respectively. PCR conditions were as follows: for KAPA 2G Robust Kit, 
initial denaturation at 95°C for 3 minutes, denaturation at 95°C for 30 seconds, annealing at 60°C 
for 30 seconds, extension at 72°C for 30 seconds and final extension at 72°C for 1 minutes before 
cooling down to 4°C. Denaturation, annealing and extension steps were repeated for 30 cycles. 
Meanwhile for KAPA 2G Fast ReadyMix PCR Kit, initial denaturation at 95°C for 3 minutes, 
denaturation at 95°C for 15 seconds, annealing at 60°C for 15 seconds, extension at 72°C for 1 
seconds and final extension at 72°C for 1 minutes before cooling down to 4°C. Denaturation, 
annealing and extension steps were repeated for 30 cycles. PCR was performed using C1000 
Touch Thermal Cycler (Biorad).  
 PCR amplification was confirmed by performing size separation electrophoresis in a 1.5% 
agarose gel at 100 V for 60 minutes. Exo/SAP Go – PCR Purification Kit (Grisp) was used for PCR 
products clean up before the concentration of the PCR products was measured using the 
Nanodrop 2000c Spectrophotometer (Thermo Scientific). Afterwards, the PCR products were 
diluted to 80 ng/µl and 5 µl were sent for sequencing with Sanger Method.  
 
3.5 Cell Lines 
HCC1954 and T-47D cell lines were maintained in RPMI medium supplemented with 10% 
of foetal bovine serum and 1% of penicillin. Meanwhile MDA-MB-231 cell line was maintained in 
DMEM medium supplemented with 10% of foetal bovine serum and 1% of penicillin. All HCC1954, 
T-47D and MDA-MB-231 cell lines were obtained from our collection. HCC1954, T-47D and MDA-
MD-231 are all cancer cell lines with HCC1954 and MDA-MD-231 being estrogen receptor 
negative (ER-) meanwhile T-47D is an estrogen receptor positive (ER+). 
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Other cell lines analysed during this master project, either in silico or experimentally are: 
human mammary epithelial cells (HMEC), human mammary fibroblasts (HMF), oestrogen 
receptor negative cancer mammary epithelial cells (MCF10A) and oestrogen receptor positive 
cancer mammary epithelial cells (MCF-7). 
 
 
3.6 Nuclear Protein Extraction 
Nuclear protein extraction was prepared using the NE-PER Nuclear and Cytoplasmic 
Extraction Reagents kit (Thermo Scientific, Life Technologies) following the protocol stated by the 
manufacturer. Nuclear protein extract concentration was measured using Nanodrop 2000c 
Spectrophotometer (Thermo Scientific) in accordance to the manufacturer’s instructions.  
 
 
3.7 Electrophoretic Mobility Shift Analysis 
Electrophoretic Mobility Shift Analysis is an approach that allows the detection of protein 
and nucleic acid interactions42. This method is based on electrophoretic mobility shift between 
protein and nucleic acid binding complexes using non-denaturing polyacrylamide gel42,43.  
A double strand oligonucleotide containing a putative binding sequence is labelled with a 
non-radioactive marker, biotin. This labelled oligonucleotide is then mixed with nuclear extract 
in order for them to form protein-nucleic acid binding complexes. If protein binds to the labelled 
oligonucleotide, the binding complex will migrate slower than the unbound oligonucleotide 
through the polyacrylamide gel, creating a shift. 
Competitive binding assay is performed by adding unlabelled oligonucleotides in order to 
test the binding specificity of a protein to the target sequence43. Subsequently, antibody binding 
or super-shift assay can be performed in order to identify the protein present in the protein-
nucleic acid complex44. This binding complex consist of antibody, protein and nucleic acid will 
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cause an even lower mobility of protein – nucleic acid complex resulting in a super shift on the 
gel (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7.1 Oligonucleotide Labelling 
Oligonucleotides with 35 base pairs of DNA sequence neighbouring the rs2406909 SNP 
was designed (Annex 2) and a previously known oligonucleotide with a sequence complementary 
to FGFR2 locus, that binds to Oct-1 and CEBPβ proteins, was used as a positive control45. 
Oligonucleotides labelling was done by separately incorporating biotin to the 3’ end of each 
strand of complementary oligonucleotide. Afterward these complementary oligonucleotides 
were annealed to each other. Lastly, labelling efficiency was checked after the completion of 
oligonucleotides annealing process. Oligonucleotides labelling was performed using Biotin 3’ End 
DNA Labelling Kit (Life Technologies) in accordance to manufacturer’s instructions. For labelling 
Figure 10: Overview of EMSA method. On the left is the reaction assay scheme for EMSA. On the right is the expected 
EMSA band scheme seen on gel. Life Technologies Inc., 2015. 
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efficiency, dot blot using hand spotting protocol was chosen and the detection was done using 
the Chemiluminescent Nucleic Acid Detection Module (Life Technologies).  
 
 
3.7.2 Protein-Nucleic Acid Binding and Competition Assay 
 All EMSAs were performed using Light Shift Chemiluminescent EMSA Kit (Life 
Technologies). The EMSA for protein-nucleic acid binding complexes detection were performed 
separately for the two alleles of each SNP.  EMSA was carried out with 20 fmol biotin 3’ end 
labelled oligonucleotides, which were incubated for 15 minutes at room temperature with 15 µg 
nuclear extract in a final volume of 20 µL binding buffer (20 mM Hepes, 0.1 mM ZnCl2, 10 % 
glycerol, 1 mM DTT, 1x protein inhibitor and 10 ng/µL poly (dI.dC)). A 4-20% TBE Gel (Life 
Technologies) polyacrylamide gradient gel was used to migrate the samples at 100 V for 2 hour. 
The protein-nucleic acid complexes were then transferred from the gel onto a nylon membrane 
using a Mini Trans-Blot Electrophoretic Transfer Cell (Biorad) at 80 V for 1 hour. Crosslink and 
detection were performed in accordance to manufacturer’s instructions. 
Following the results obtained in the protein-nucleic acid binding assay, the SNP alleles 
that showed clear indication of protein binding were further analysed with EMSA competition 
assay. The competition assays were performed by adding different concentrations of unlabelled 
oligonucleotide for the alleles of interest. The remaining EMSA protocol was the same as 
described above for protein-nucleic acid binding assay. 
 
 
3.8 Haplotypes Analysis 
 Haplotypes analysis was performed using genotypes information for all tSNPs and rSNPs 
except for rs226198. SNP rs226198 did not have imputation genotypes as well as proxy SNP in 
complete LD with it. Therefore, we performed sample genotyping for rs226198. We also did not 
have genotypes information for GWAS SNP. However, a proxy SNP rs6888977, that is in complete 
LD (r2 = 1) with GWAS SNP was identified. Haploview software was used to analyse haplotype 
structure for tSNPs, rSNPs and proxy GWAS SNP46.  
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3.9 Gene Expression 
 Real-time PCR allows PCR amplification and detection into a single step, hence eliminating 
the need to detect products using gel electrophoresis and enables the PCR products to be 
quantified. Real-time PCR uses fluorescent dyes to detect the accumulation of PCR products 
during the exponential phase of the reaction. 
 Amplification plot in a real-time PCR is performed through the detection and 
quantification of a fluorescent reporter signal. Baseline for the real-time PCR is established first, 
before the threshold line and cycle thresholds (Ct) are calculated, in the beginning of the 
exponential phase. Threshold line is the level of detection, where a reaction reaches a fluorescent 
intensity, above the established baseline. Ct is the point of intersection between the 
amplification curve and the threshold line47, and is a relative measure of the concentration of the 
target product, in the PCR reaction. In the exponential phase it is assumed that the signal intensity 
is in direct proportion to the amount of PCR product and, therefore, the amount of fluorescence 
is registered at each cycle and measured.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Ct value 
Figure 11: Real time PCR detection of product in exponential phase. Ct values are calculated by determining the point at which 
the fluorescence exceeds a threshold limit. 
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There are several types of detection chemistry used in qPCR, namely: DNA binding dyes, 
hybridization probes, hairpin probes and Taqman probes. In this study, we used the Taqman 
probes that utilizes the 5’ nuclease activity of DNA polymerase to hydrolyse a hybridization probe 
bound to its target product. The probe emits a fluorescent signal when cleaved based on the 
fluorescent resonance energy transfer (FRET) principle. The probe 3’ end is non-extendable and 
is dual-labelled, with a reporter fluorochrome such as FAM or HEX and a quencher fluorochrome. 
The probe is designed to anneal to the target sequence internally of the primer during the 
annealing and extension phase of the PCR reaction. When the probe is in its intact and free form, 
it does not emit any fluorescence because the fluorescence of the reporter dye is absorbed by 
the quencher dye by the principle of FRET. However, upon extension of the nascent strand, the 
probe become degraded by the activity of 5’ to 3’ exonuclease activity of the Taq polymerase, 
resulting in an increase of reporter fluorescent emission which is proportional to the increase in 
PCR product (Figure 12)48.  
  
Figure 12: Detection chemistry in qPCR by hydrolysis of Taqman probe. In free and intact form, the Taqman probe does not emit 
fluorescence. In the PCR reaction, the probe anneal to target sequence and then get hydrolysed by 5’ to 3’ exonuclease activity of 
the Taqman polymerase which later cleavage the reporter dye away from the quencher dye. This enable the reporter dye to emit 
fluorescent by the principle of fluorescent resonance energy transfer (FRET).   
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RPS23 gene expression levels were assayed using quantitative real-time polymerase chain 
reaction (qPCR) method (Hs01374150_g1 probe) with 29 complementary DNA (cDNA) samples 
prepared from normal breast tissue, already existing in the laboratory. The GAPDH gene was used 
as housekeeping gene and its expression was also measured for the 29 samples. A serial dilution 
using a DNA sample from a MCF-7 cell line was included for both RPS23 and GAPDH assays in 
order to construct a standard curve for gene expression quantification. Serial dilutions were set 
at 1:1, 1:2, 1:10, 1:20, 1:100, 1:1,000 and 1:10,000. Five ng/µL of cDNA of each sample were 
reconstituted to final volume of 5 µL by a master mix consisted of Taqman Gene Expression 
Assays ((20X, Applied Biosystems), Kapa Probe Fast Universal qPCR Kit ((2X), Kapa Biosystems) 
and DNase/RNase free water (Life Technologies).  Each sample (for RPS23, GAPDH assays, as well 
as serial dilutions) was assayed in triplicate and samples were assayed on the same 384 well plate.  
Ct values were obtained from Bio-rad CFX Manager Software and analysed on Microsoft 
Excel 2013. Calculation of RPS23 gene expression levels for each sample were obtained from 
averaged Ct values and normalized according to GADPH measurements, for each sample 
individually. Total gene expression data for ATG10 and, ATP6AP1L have been previously 
measured with Illumina HumanHT-12 expression beadchips for 27 samples in common with the 
DAE map (Probes ID: ILMN_2206098 and ILMN_1755990 for ATG10 and ATP6AP1L, respectively).  
For eQTL analysis, RPS23, ATG10 and ATP6AP1L expression levels were plotted against 
genotypes at each candidate rSNP. For all rSNPs, a logistic regression using log-additive model 
was applied to assess the association of genotypes with total gene expression levels. Statistical 
analysis and graphics were performed using R software.  
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Chapter 4: Results 
 
4.1 Identification of Candidate rSNPs in the 5q14.2 Locus 
 One of the objectives of this study was to identify cis-acting regulatory SNPs that may be 
responsible for the breast cancer risk association identified for SNP rs770792112. This was 
performed by analysing the linkage disequilibrium between the GWAS SNP with the five tSNPs in 
the ATG10-RPS23-ATP6AP1L locus: rs10068160, rs150934, rs10044824, rs226202 and 
rs7733620. Candidate rSNPs list was generated by selecting SNPs with LD, r2 ≥ 0.4 with the GWAS 
SNP, based on DAE distribution showing Scenario 2, according to Xiao et. al., for all tSNPs22. This 
scenario, suggests a strong, but not complete, LD between the regulatory SNP and the 
transcribed SNP. 
 We retrieved 125 candidate rSNPs with the established LD cut-off from HaploReg V3 
database. Additional functional data were sought from RegulomeDB and The Human Protein 
Atlas databases. From the 125 candidate SNPs, six SNPs were found to have evidence of 
regulatory functions in breast tissue or breast cell lines, as shown in Table 1. Information obtained 
from RegulomeDB showed that each of these six candidate rSNPs have more than one functional 
evidence such as being an eQTL, having transcription factor (TF) binding, matched TF motif or 
DNAseI hypersensitivity.  
Table 1: RegulomeDB scores for the candidate regulatory SNPs. 
   SNP RegulomeDB Score 
rs226198 
1a 
rs17247678 
rs2406909 
 1b 
rs10036937 
rs2407153  1d 
rs6880209 1f 
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RegulomeDB categorises SNPs with functional evidence according to a scoring scheme. 
SNPs with a score of 1 are likely to affect binding and are linked to expression of a gene target 
while SNPS with score of 2 are likely to affect binding and score 3 are less likely to affect binding. 
Lastly, SNPs with scores from 4 to 6 have minimal binding evidence. Scoring of a to f indicates the 
decrease of functional evidence in a SNP.  
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4.2 Analysis of Candidate rSNPs in the 5q14.2 Locus 
 The six candidate rSNPs were categorised into 4 regions in the regulatory landscape in the 
5q14.2 locus, as visualised in Figure 13, using the UCSC Genome Browser. Region 1 contained one 
candidate rSNP rs24060909. In region 2, two candidate rSNPs rs10036937 as well as rs2407153. 
In region 3, also two candidate rSNPs rs226198 and rs6880209. Finally region 4 had candidate 
rSNP rs17247678 (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Genomic view of the 5q14.2 locus showed information on histone modifications such as 
H3K4Me3, H3K4Me1 and H3K27AC, which are markers for promoters, enhancers and active 
regulatory elements, respectively. There was also information on DNase I hypersensitivity site 
(DHS), which is a region that organises DNA structure and acts as regulator of transcription by 
enabling or restricting protein binding49,50. CTCF in MCF-7, a region known to mediate chromatin 
loop and causes accessibility to regulatory elements region either to be activated or blocked, 
hence influencing transcriptional regulation51. Lastly, chromatin modifications in HMEC. 
Figure 13: Genomic view of the 5q.14.2 locus with functional regulatory evidence. From the top to bottom of the figure are shown 
the candidate rSNPs, the RefSeq genes mapped to the area of interest around the 5q14.2 locus, information on histone 
modifications, DNase I hypersensitivity clusters, CTCF binding region in MCF-7 and chromatin modifications in HMEC according to 
the Genome Browser (http://genome-euro.ucsc.edu/index.html). 
Region 1 Region 2 Region 3 Region 4 
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4.2.1 Region 1: Candidate rSNP rs2406909 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In region 1, candidate rSNP rs2406909 was found to overlap a DHS. Results from our DAE 
mapping analysis showed that this candidate rSNP rs2406909 was associated with DAE at the 
tSNPs rs10044824 (p-value = 3.90 x- 10-4) and rs7733620 (p-value = 3.97 x 10-6) (Figure 15), both 
located in ATG10. From the DAE mapping analysis, we observed that when individuals are 
homozygous for this candidate rSNP they show equal levels of transcription of the two alleles of 
the tSNP. Meanwhile individuals heterozygous for this SNP display DAE, suggesting this rSNP as 
a potential rSNP. 
  
Figure 14: Genomic view of the region 1: rSNP rs2406909 with functional evidence. From top to bottom of the figure is shown the 
candidate rSNP, the RefSeq gene mapped to the area of interest around the 5q14.2 locus, information on histone modifications, 
DNase I hypersensitivity site, CTCF binding region in MCF-7 and chromatin modifications in HMEC according to the Genome 
Browser (http://genome-euro.ucsc.edu/index.html). This candidate rSNP overlaps DHS region. 
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As rs2406909 was located in a regulatory element region, we searched for evidence of TF 
binding. Position Weight Matrix (PWM) data analysis (from the Haploreg database) showed that 
several predicted TFs (HDX, Nanog, Pou2f2, TEF, YY1 and p300) with different mass weight, 
ranging from 300 kDa to 30 kDa, have different binding affinity to the two alleles of this SNP, as 
shown in Table 2. We were not able to obtain any ChIP-seq information from the CCLE database 
for this candidate rSNP. Therefore, we performed EMSA analysis in order to verify if there was 
any in vitro TF binding potential with our rSNP rs2406909, as suggested in PMW analysis.  
 
Table 2: Predicted transcription factor binding and protein mass weight, for candidate rSNP, rs2406909, in Haploreg V3 database. 
Position Matrix Weight 
(PWM) 
Reference 
Allele 
Alternative 
Allele 
Protein Mass Weight 
(kDa) 
HDX 9.4 12.8 77 
Nanog 11.8 5.3 35 
Pou2f2 12.2 6.5 51 
TEF 1.5 13.5 33 
YY1 10.9 2.3 45 
p300 6.6 11.6 264 
 
  
Figure 15: DAE mapping analysis for rSNP rs2406909. The x-axis represent the genotypes meanwhile the y-axis represent the 
DAE ratio seen at the tSNP. Samples observed in between the dotted lines have equal expression hence not causing the effect of 
DAE meanwhile samples observed above or below the dotted lines have unequal expression hence causing the effect of DAE. 
DAE pattern at the tSNP are identified by grouping the rSNP sample genotypes. [DAE ratio, log 2 (1.5) = 0.584]. (A) rSNP 
rs24006909 with tSNP rs10044824. (B) rSNP rs2406909 with tSNP rs7733620. 
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Before performing EMSA analysis, biotin labelled oligonucleotide efficiency estimation for 
the candidate rSNP’s alleles was determined to be at 100% (Annex 3). In Figure 16, are shown 
the results for an EMSA for rs2406909 using protein nuclear extract from the breast cancer cell 
line MCF-7. Lane 1 corresponds to oligonucleotides of FGFR2 that was used as a positive control, 
meanwhile lanes 2 and 3 contain oligonucleotides that have the specific T and C allele sequences, 
respectively. From the gel image, both showed a shift, suggesting that both bind to protein 
existing in the MCF-7 nuclear extract. Based on the reference of protein marker, the size of the 
shift corresponded to mass weight ranging from 63 to 75 kDa. 
Competition assays were performed, showing in lanes 4 until 14. Lanes 4 to 9 correspond 
to labelled oligonucleotide containing the T allele, meanwhile lanes 9 to 14 correspond to labelled 
oligonucleotide containing the C allele. Competition assays were done by adding different 
concentrations of unlabelled oligonucleotides. These were set at the same concentration as the 
labelled oligonucleotide, 33-fold higher and 100-fold higher, except for lanes 10 and 11, where 
the competition concentrations were set at 33-fold higher and 100-fold higher. Lanes 4, 5, 6, 10 
and 11 correspond to T allele competition meanwhile lanes 7, 8, 9, 12, 13 and 14 correspond to 
C allele competition.  
In lanes 4, 7 and 12, corresponding to the same concentration of labelled and unlabelled 
oligonucleotides, we can see that the bands are weaker compared to the lanes that do not have 
competition (lane 2 and 3). This suggests that protein-nucleic acid binding truly occurred for both 
alleles, as both labelled and unlabelled oligonucleotides bind to protein. This suggestion is further 
supported by the absence of bands in lanes that contain 33-fold higher and 100-fold higher 
unlabelled oligonucleotides.  
The EMSA was repeated with the same conditions using a different breast cancer cell line, 
MDA-MD-231, which does not express oestrogen receptor (ER-). The EMSA result is shown in 
Figure 17, where we can see bands in lanes 2 and 3 that correspond to both the T and C alleles 
labelled oligonucleotides, respectively. We can also see bands in lanes 3, 7 and 12 even though 
it contained competitor oligonucleotides. However, as the concentration of competitor 
increased, the bands gradually disappeared. This suggests that the protein binding has the same 
affinity for both alleles, even in different cell lines (ER+ vs ER-). Since there was protein binding 
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for both alleles, this does not explain the DAE. Therefore, this candidate could not be the SNP 
responsible for the DAE observed at tSNPs rs10044824 (ATG10) and rs7733620 (ATG10). 
Therefore, was excluded from further analysis.  
 
 
  
Figure 16: In vitro protein-nucleic acid binding and competition binding studies. EMSA analysis was performed using MCF-7 nuclear 
extract. Lane 1 corresponds to oligonucleotides of FGFR2 that was used as a positive control, meanwhile lanes 2 and 3 correspond 
to oligonucleotides that have the specific T and C allele sequences, respectively. Lanes 4 to 9 correspond to labelled oligonucleotide 
containing the T allele, meanwhile lanes 9 to 14 correspond to labelled oligonucleotide containing the C allele. For competition 
assays, unlabelled oligonucleotide in lanes 4 to 14 were set at the same concentration as the labelled oligonucleotide, 33-fold higher 
and 100-fold higher, except for lanes 10 and 11, where the competition concentrations were set at 33-fold higher and 100-fold 
higher, respectively. Lanes 4, 5, 6, 10 and 11 correspond to T allele competition meanwhile lanes 7, 8, 9, 12, 13 and 14 correspond 
to C allele competition. A indicate the top of the band (well). B indicate the specific bands for protein-nucleic acid binding. C indicate 
the free unbound oligonucleotides. 
* represent the labelled oligonucleotide.  
+ represent the present of oligonucleotide in the reaction assay. 
- represent the absent of oligonucleotide in the reaction assay. 
 represent the increase of oligonucleotide concentration.  
FGFR2* + - - - - - - - - - - - - - 
Competition: 
T allele - - - + + + - - - + + - - - 
C allele - - - - - - + + + - - + + + 
T allele* - + - + + + + + + - - - - - 
C allele * - - + - - - - - - + + + + + 
 1 2 3
3
4 5 6 7 8 9 10 11 12 13 14 
C 
B 
A 
Protein 
Marker 
75 kDa 
63 kDa 
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Figure 17: In vitro protein-nucleic acid binding and competition binding studies. EMSA analysis was performed using MDA-MB-231 
nuclear extract. Lane 1 corresponds to oligonucleotides of FGFR2 that was used as a positive control, meanwhile lanes 2 and 3 
correspond to oligonucleotides that have the specific T and C allele sequences, respectively. Lanes 4 to 9 correspond to labelled 
oligonucleotide containing the T allele, meanwhile lanes 9 to 14 correspond to labelled oligonucleotide containing the C allele. For 
competition assays, unlabelled oligonucleotide in lanes 4 to 14 were set at the same concentration as the labelled oligonucleotide, 
33-fold higher and 100-fold higher, except for lanes 10 and 11, where the competition concentrations were set at 33-fold higher 
and 100-fold higher, respectively. Lanes 4, 5, 6, 10 and 11 correspond to T allele competition meanwhile lanes 7, 8, 9, 12, 13 and 
14 correspond to C allele competition. A indicate the top of the band (well). B indicate the specific bands for protein-nucleic acid 
binding. C indicate the free unbound oligonucleotides. 
* represent the labelled oligonucleotide.  
+ represent the present of oligonucleotide in the reaction assay. 
- represent the absent of oligonucleotide in the reaction assay. 
 represent the increase of oligonucleotide concentration.  
 
A 
D 
B 
C 
Competition: 
FGFR2* + - - - - - - - - - - - - - 
T allele - - - + + + - - - + + - - - 
C allele - - - - - - + + + - - + + + 
T allele * - + - + + + + + + - - - - - 
C allele * - - + - - - - - - + + + + + 
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4.2.2 Region 2: Candidate rSNPs rs10036937 and rs2407153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In region 2, both candidate rSNPs rs10036937 and rs2407153 were found to overlap a 
CTCF binding region as well as DHS region. This is an indication that this region is under the 
influence of chromatin looping, as well as activation, or restriction, of protein binding by DHS.  
For candidate rSNP rs10036937, we observed in DAE mapping analysis that there was no 
significant association with tSNP rs7733620 (p-value = 0.081) located at ATG10 and tSNP 
rs226202 (p = 0.542) located at RPS23. As for rSNP candidate rs2407153, after genotyping 25 
samples, we verified that there was a significant association with tSNP rs10044824 (ATG10) (p-
value = 1.23 x 10-5) (Figure 19). However, no significant association for tSNP rs7733620 (ATG10) 
with p-value = 0.379 or tSNP rs226202 (RPS23) with p-value = 0.517 (Annex 4). 
  
Figure 18: Genomic view of the region 2: rSNP rs10036937 and rs2407153 with functional evidence. From top to bottom of the 
figure are shown the candidate rSNPs, the RefSeq genes mapped to the area of interest around the 5q14.2 locus, information on 
histone modifications, DNase I hypersensitivity clusters, CTCF binding region in MCF-7 and chromatin modifications in HMEC 
according to the Genome Browser (http://genome-euro.ucsc.edu/index.html). These candidate rSNPs overlap DHS and CTCF 
region. 
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We proceeded with seeking for evidence of TF binding and from the CCLE database, we 
were able to obtain evidence of CTCF binding to candidate rSNP rs10036937 in MCF-7, HMF and 
HMEC cell lines. In the MCF-7 cell line, there was CTCF binding data from several ChIP-seq 
experiments and most of the reads count were higher than 10, with the maximum coverage at 
24. The CTCF binding in MCF-7 only occurred to the C allele. As for HMF and HMEC cell lines, we 
saw preferential CTCF binding to the C allele compared to the G allele. However, for HMF, we 
only identified data from two ChIP-seq experiments, with preferential CTCF binding to the C 
allele, also with reads count of 5 and 14 (maximum coverage at 23). Meanwhile in HMEC, total 
reads count for all experiments were less than 10 with preferential binding reads count between 
2 and 4 (Annex 5). Published data also revealed that rs2407153 is bound by CTCF in the MCF-7 
cell line. However, all the ChIP-seq experiments reads count were below 3 (Annex 5). 
Candidate rSNP rs2407153 showed a significance for association at tSNP rs10044824 
(ATG10), in DAE mapping analysis consisted of 25 genotyped samples. However, both rs2407153 
and rs10036937, lacked evidence for regulatory elements and had low reads count for CTCF 
binding. Therefore, these candidate rSNPs were excluded from further study analysis.       
 
 
Figure 19: DAE mapping analysis for rs2407153. The x-axis represent the genotypes meanwhile the y-axis represent the DAE 
ratio seen at the tSNP. Samples observed in between the dotted lines have equal expression hence not causing the effect of DAE 
meanwhile samples observed above or below the dotted lines have unequal expression hence causing the effect of DAE. DAE 
pattern at the tSNP are identified by grouping the rSNP sample genotypes. [DAE ratio, log 2 (1.5) = 0.584]. This is an rSNP 
rs2407153 with tSNP rs10044824. 
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4.2.3 Region 3: Candidate rSNPs rs226198 and rs6880209 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Our in silico analysis revealed that both candidate rSNPs rs226198 and rs6880209, in 
region 3, were found to overlap an active regulatory element peak (H3K27AC, histone H3 
acetylated at lysine 27 is a histone that flank active enhancers), as well as an enhancer peak 
(H3K4Me3, H3 monomethylated at lysine 4 is also a histone mark for enhancer)37. Besides these 
histone modification regions, it was revealed that both were also overlapping a DHS and a CTCF 
binding region (Figure 20).  
As both candidate rSNPs rs226198 and rs6880209 overlap several regulatory element 
regions, it seemed to be promising candidates. Although rs226198 showed no significance for 
association with tSNP rs226202 (RPS23) with p-value = 0.069, in a DAE mapping analysis consisted 
of 25 genotyped samples. It did showed a trend for association with the DAE pattern (Figure 21). 
Figure 20: Genomic view of the region 3: rSNPs rs226198 and rs6880209 with functional evidence. From top to bottom of the 
figure are shown the candidate rSNPs, the RefSeq genes mapped to the area of interest around the 5q14.2 locus, information on 
histone modifications, DNase I hypersensitivity clusters, CTCF binding region in MCF-7 and chromatin modifications in HMEC 
according to the Genome Browser (http://genome-euro.ucsc.edu/index.html). These candidate rSNPs overlap active enhancer 
peak, DHS and CTCF region. 
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For candidate rSNP rs6880209, we verified that this rSNP was associated with the DAE 
distribution of tSNP rs150934 (ATP6AP1L) with p-value = 6.09 x 10-3 (Figure 21). 
 
 
 
 
 
 
 
 
 
 
 
In silico analysis from CCLE database, showed that rs226198 had evidence of c-Myc and 
POL2 proteins binding, in MCF-7 and MCF10A breast cancer cell lines. In MCF-7 cell line, both 
proteins have preferential binding to the C allele. For c-Myc, most of the ChIP-seq experiments 
read counts were higher than 20, with the highest reads count at 565 (Figure 22). Meanwhile, for 
POL2, most of the ChIP-seq experiments read counts were more than 6 with the highest coverage 
at 11. In MCF10A, c-Myc and POL2 were also revealed to have a slight preferentially binding to 
the T allele (Annex 5). 
 
 
 
 
 
 
 
 
Total Reads Count: 612 
C     : 565 (92 %) 
T     : 42 (7 %) 
Figure 22: ChIP-seq results in MCF-7 cell line for c-Myc at the rSNP rs226198. Data was taken from CCLE database and viewed 
with Integrative Genomics Viewer (IGV). 
Figure 21: DAE mapping analysis for rs6880209 and rs226198. The x-axis represent the genotypes meanwhile the y-axis represent 
the DAE ratio seen at the tSNP. Samples observed in between the dotted lines have equal expression hence not causing the effect 
of DAE meanwhile samples observed above or below the dotted lines have unequal expression hence causing the effect of DAE. 
DAE pattern at the tSNP are identified by grouping the rSNP sample genotypes. [DAE ratio, log 2 (1.5) = 0.584]. (A) rSNP rs6880209 
with tSNP rs150934. (B) rSNP rs226198 with tSNP rs226202. 
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It was also found that for rs6880209, there was c-Myc and POL2 proteins binding both in 
MCF-7 and MCF10A breast cancer cell lines. In MCF-7, several ChIP-seq experiments showed 
preferential c-Myc protein binding to the T allele, with the highest ChIP-seq reads count of 188 
(83%) (Figure 23). As for the POL2 protein, it also showed preferentially binding to the T allele, 
with the highest ChIP-seq reads count of 86 (72%). Meanwhile, for the MCF10A cell line, both 
proteins showed the same binding pattern as for MCF-7 cell line, but c-Myc had ChIP-seq read 
counts were lower than 20 in this cell type. Overall, all the ChIP-seq experiments point to c-Myc 
and POL2 proteins having a higher binding affinity for the T allele. 
 
 
 
 
 
 
 
We decided to include both rs226198 and rs6880209 in further analysis due to evidence 
of being located in a region with several regulatory elements and strong evidence supporting TF 
binding. Even though candidate rs226198 showed no significance associated with DAE levels at 
tSNP rs226202 (RPS23), it did showed DAE trending. This rSNP inclusion was justified by the 
limited number of genotyped samples that might have influenced the DAE mapping analysis. 
  
Total Reads Count: 227 
C      : 39  (17 %) 
T      : 188  (83 %) 
Figure 23: ChIP-seq results in MCF-7 cell line for c-Myc at the rSNP rs6880209. Data was taken from CCLE database and viewed 
with Integrative Genomics Viewer (IGV). 
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4.2.4 Region 4: Candidate rSNP rs17247678 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In region 4, it was found that, besides overlapping enhancer and active regulatory 
element peaks, candidate rSNP rs17247678 was overlapping a DHS region, as well. DAE mapping 
analysis performed for this candidate rSNP showed it was associated with the DAE distribution 
for tSNPs rs150934 (ATP6AP1L) with p-value = 2.89 x 10-3 and rs7733620 (ATG10) with p-value = 
2.40 x 10-4 (Figure 25). There was no significant association found between this candidate rSNP 
with tSNP rs226202 (RPS23) (p-value = 0.262) (Annex 4).  
  
Figure 24: Genomic view of the region 4: rSNP rs17247678 with functional evidence. From top to bottom of the figure is shown 
the candidate rSNP, the RefSeq gene mapped to the area of interest around the 5q14.2 locus, information on histone 
modifications, DNase I hypersensitivity site, CTCF binding region in MCF-7 and chromatin modifications in HMEC according to the 
Genome Browser (http://genome-euro.ucsc.edu/index.html). This candidate rSNP overlaps regulatory elements region such as 
active enhancer, DHS and CTCF binding. 
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Evidence found in CCLE database showed that there was TF binding to candidate rSNP 
rs17247678 in MCF10A cell line. STAT3 and c-FOS proteins were found to bind preferentially to 
A allele. All ChIP-seq experiments had total read counts lower than 20, with the highest ChIP-seq 
reads count in the coverage region of 28 (Figure 26). Therefore, future ChIP-seq analysis with 
higher coverage should be conducted in order to have stronger confidence about TF binding.  
  
Figure 25: DAE mapping analysis for rSNP rs17247678. The x-axis represent the genotypes meanwhile the y-axis represent the 
DAE ratio seen at the tSNP. Samples observed in between the dotted lines have equal expression hence not causing the effect 
of DAE meanwhile samples observed above or below the dotted lines have unequal expression hence causing the effect of 
DAE. DAE pattern at the tSNP are identified by grouping the rSNP sample genotypes. [DAE ratio, log 2 (1.5) = 0.584]. (A) rSNP 
rs17247678 with tSNP rs150934. (B) rSNP rs17247678 with tSNP rs7733620. 
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A 
Total Reads Count: 15 
A    : 6  (40 %) 
G    : 9  (60 %) 
B 
Total Reads Count: 20 
A    : 13  (65 %) 
G    : 7  (35 %) 
Figure 26: ChIP-seq results in MCF10A cell line for (a) c-FOS and (b) STAT3 at the rSNP rs17247678. Data was taken from CCLE 
database and viewed with Integrative Genomics Viewer (IGV). 
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4.3 Expression Quantitative Trait Loci Analysis 
 In order to assess if total gene expression levels at ATG10, RPS23 and ATP6AP1L genes 
are associated with the candidate rSNPs (rs226198, rs6880209 and rs17247678) genotypes, we 
performed eQTL analysis. We had total expression data, from microarrays experiments 
performed previously for 26 samples for ATG10 and ATP6AP1L. However, we did not have any 
data for the RPS23. Therefore, we conducted gene expression analysis using Taqman real-time 
PCR for this gene and obtained total expression results for 22 samples (during quality control, 
five samples without triplicate results were excluded). From eQTL analysis, we found no 
significant evidence of eQTL in total gene expression with our rSNPs genotypes (Annex 6).   
 
 
4.4 Linkage Disequilibrium Structure and Haplotypes Block 
All five tSNPs, candidate rSNPs with strong functional evidence (rs226198, rs6880209 and 
rs17247678) and a proxy for the GWAS SNP (rs6888977) were analysed for LD structure and 
haplotypes using the genotype information of our samples. We did not have genotype 
information for the GWAS SNP rs7707921, so we used a proxy SNP that was in complete LD (r2 = 
1 in CEU HapMap population), rs6888977, which was genotyped from our previous experiment. 
For rSNP rs226198, we only had genotype information for 47 out of our 64 samples. 
Haplotype analysis revealed that the region where our candidate rSNPs, the GWAS proxy 
variant and the tSNPs are located, is divided in two haplotype blocks. All the SNPs belong to one 
of the blocks except for rs17247578. As we can see in Figure 27, Block 1, includes: four tSNPs 
(rs10068160, rs7733620, rs10044824, rs226202) which corresponded to ATG10 and RPS23 
genes, proxy SNP for GWAS (rs6888977) in the ATG10 gene and finally the rSNP rs226198. Block 
2, contains one tSNP rs150934 located in the ATP6AP1L gene and one rSNP rs6880209. 
Meanwhile our rSNP rs17247678 was located outside of the haplotype blocks. 
Haplotype analysis also revealed that Block 1, had eight haplotypes and Block 2, there had 
four haplotypes (Figure 28).  
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The minor allele of the GWAS SNP rs7707921 (T allele) that confers protection to breast 
cancer risk, is represented Figure 24 by the C allele of rs6888977, which that is present in 
Haplotypes 2, 5 and 8. Meanwhile from our DAE data, the minor alleles from the tSNPs 
rs10068160 (G), rs7733620 (T) and rs10044824 (C) from ATG10 were over expressed than the 
common alleles (highlighted with red box). The minor allele of the tSNP rs226202 (C) corresponds 
to less expression of the RPS23 gene (highlighted with blue box) and minor allele of the tSNP 
rs150934 (C) correspond to higher expression of the from ATP6AP1L gene (highlighted with green 
box).  
Interestingly, Haplotype 2 in Block 1 (frequency approximately 20% includes all the alleles 
preferentially expressed of the gene ATG10, the allele that less expressed of the gene RPS23, and 
the allele that confers protection of the GWAS study. Furthermore, it is mostly inherited together 
with Haplotype 10 from Block 2, which contains the preferentially expressed allele of the gene 
ATP6AP1L. Interestingly, Haplotype 2 also contains the G allele of rs226198 and Haplotype 10 the 
T allele of rs6880209, which were observed to have higher binding affinity to c-Myc and POL2. 
Haplotype 1 (frequency of approximately 50%), has the alternatives alleles of Haplotype 2, 
including the GWAS risk allele. 
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Figure 27: Linkage disequilibrium plot for the analysed proxy GWAS SNP (rs6888977), DAE SNPs (rs10068160, rs7733620, 
rs10044824, rs226202, rs150934) and rSNPs (rs226198, rs6880209, rs17247678). The SNP ID is displayed along the top of the 
diagram. This plot was obtained from Haploview using r2 colour scheme (black indicating r2=1, with different shades of grey 
indicating 0 < r2 < 1). In addition, values in the plot indicate r2 values for pairwise comparisons between the SNPs. Blocks were 
defined using the Spine method. Black triangles denote the two haplotypes blocks. 
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Haplotype 2 
Haplotype 3 
Haplotype 4 
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Haplotype 6 
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Haplotype 12 
Figure 28: Haplotype block and haplotype frequency in the 5q14.2 locus. The haplotype frequencies are shown to the right side of 
each haplotype. The SNP numbers at the top correspond to those in the LD plot (Figure 27). The tSNPs used in this analysis are 
shown in the coloured box. Red correspond to ATG10 gene, blue correspond to RPS23 gene and green correspond to ATP6AP1L 
gene. 
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Chapter 5: Discussion 
 
 The aim of this study was to identify cis-acting regulatory SNPs that may be responsible 
for the association identified at the meta-analysis GWASs SNP rs7707921. The locus chosen for 
analysis in this thesis contained one GWAS SNP and five DAE SNPs. We began by identifying SNPs 
in LD with GWAS SNP. Out of the 125 initial candidate rSNPs obtained from in silico analysis, with 
an LD cut-off r2 ≥ 0.4 with the GWAS SNP, only six were selected to be analysed as it showed 
evidence of being cis-acting regulatory variants. The cut-off were chosen based on DAE 
distribution seen in tSNPs showing a trend similar to scenario 2 in Xiao et. al.22, suggesting a 
strong but incomplete LD, between the regulatory SNP and the transcribed SNP. Our study 
identified three potential rSNPs: rs226198, rs68880209 and rs17247678. These might be involved 
in the regulation of gene(s) showing DAE, and may also be responsible for the risk captured by 
the GWAS SNP rs7707921. 
 Our findings revealed that candidate rSNPs rs226198 and rs68880209, in addition to being 
located in the promoter region shared by the RPS23 and ATP6AP1L genes, also have preferential 
binding of c-Myc and POL2 (T and C alleles, respectively). These results were observed in two 
breast cancer cell lines, although for one the number of reads was low (n ≤ 20). DAE mapping 
analysis indicated that rs68880209 was associated with DAE levels of the ATP6AP1L gene, and 
rs226198 showed a trend for association with RPS23 DAE ratios, although the latter did not reach 
significance. However, it is important to mention that there was not enough genotype 
information for rs226198, which might hinder the results. 
 In the case of candidate rSNP rs17247678, we found it is located in a STAT3 binding site, 
with higher binding affinity to the A allele in MCF10A cell line. Once more, as the number of reads 
was low (n ≤ 20), we cannot conclude with confidence on the preferential allelic binding. 
Nevertheless, it is reassuring that c-FOS, a common co-factor of STAT3, has a binding site located 
immediately upstream of this position. 
We decided to exclude the three other candidate rSNPs based on insufficient evidence 
supporting their role as regulatory SNPs. Candidate rSNP rs2406909 is located in a regulatory 
element and DAE mapping analysis revealed it was associated with DAE ratios in tSNPs 
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rs10044824 and rs7733620 (both in ATG10 gene). However, EMSA experiments showed equal TF 
binding affinity to both alleles, which cannot explain the DAE pattern obtained for these tSNPs. 
The band shift seen in the EMSA corresponded to a mass weight ranging from 63 kDa to 75 Da, 
suggesting the bound protein could have mass weight within that range. Thus, based on the PWM 
analysis in Table 2, the possible bound protein could either be YY1 or Pou2f2. However, this can 
only be verified with further analysis by performing competition assays or super shift assays in 
EMSA42,43, or by using mass spectrometry52. Nevertheless, even though this candidate rSNP could 
not possibly be the SNP associated with DAE at rs10044824 and rs7733620, it is probably in high 
LD with the actual rSNP that is regulating these genes.  
As for the other two candidate rSNPs, rs10036937 and rs2407153, both were located in a 
region that has CTCF binding. CTCF binding is known to mediate long-range chromatin looping, 
which facilitates the activation or insulation of regulatory elements51. Nevertheless, both 
candidate rSNPs had low ChIP-seq reads count (n ≤ 20), which poses uncertainties on the 
difference of binding affinity between alleles seen in the experiments. Nothnagel et. al. suggested 
reads count should have higher value of 20, in order to infer allelic imbalance binding 53. DAE 
mapping analysis showed that only rSNP rs2407153 had a significant associated at tSNP 
rs10044824. However, it is important to mention that there was not enough genotype 
information for rs2407153, which might hinder the results. Therefore, it supported the idea that 
these two SNPs were not the cis-acting regulatory SNP responsible for DAE at these genes.  
  Undoubtedly, there were more candidate rSNPs in the preliminary list than the six SNPs 
described in this work. However, filtering criteria were applied in order to rank potential rSNPs 
on priority to be studied. These criteria were: (1) evidence of being located in regulatory 
elements, (2) located in a DHS, (3) preferentially allelic TF binding, (4) potential of being involved 
in CTCF binding. This approach shortlists candidate rSNPs but there is the possibility that some 
SNPs with a functional effect have been missed (false negatives). Currently we believe that the 
regulation of the genes in locus 5q14.2 is a complex interaction between several rSNPs, and we 
are carrying further experiments to confirm this.  
 We have taken two approaches in order to identify cis-acting regulatory variants: one is 
through eQTL search and the other is based on DAE mapping23. Therefore to compare these two 
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approaches, we also performed eQTL analysis with our samples in order to assess total gene 
expression association with our rSNPs genotypes. For eQTL analysis, we used total gene 
expression data from 26 samples for ATG10 and ATP6AP1L and 22 samples for RPS23.  
In Michailidou et. al. study, they found a strong association of total expression in RPS23 
with GWAS SNP rs7707921 (with AK092335_1_1696 probe, p = 2.0 x 10-15 in tumours, p = 1.11 x 
10-4 in normal tissue, with AK092335_1_1335, p = 4.30 x 10-11 in tumours and p = 3.23 x 10-2 in 
normal tissue) and a weak association with the expression of ATP6AP1L (p = 5.6 x 10-5 in tumours 
and p = 0.066 in normal tissue)12. However, they were not able to identify a causal gene.  
Through our DAE approach, we were able to identify cis-regulation in the three genes in 
locus 5q14 (ATG10, RPS23 and ATP6AP1L) and identified three possible rSNPs that might be 
involved in the regulation of these genes. We performed eQTL analysis with our rSNP genotypes 
information, and found that there was no significant association between the rSNPs and the three 
genes, supporting our hypothesis that DAE is a more efficient approach to identify cis-acting 
regulatory variants.  
One possible explanation for eQTL to fail to detect cis-regulating signals has to do with 
feedback control mechanisms in the cell. Take for example, three genotypes, AA, AB and BB. The 
expression of allele A is higher but the overall expression of the homozygous AA is strongly 
controlled by the feedback control mechanism. Meanwhile homozygous BB has lower 
expression, therefore feedback control mechanism is not activated. As for heterozygous AB, it 
has intermediate levels of feedback control. Consequently, in total gene expression, variations 
between individuals are not strongly evident due to this feedback control mechanism. However, 
allelic output in the heterozygous AB, still indicate the difference between cis-acting regulatory 
alleles. Even if a strong feedback control is applied to heterozygous AB, it still can be measured 
using DAE, as both alleles in heterozygous are under equal feedback control54. 
 A housekeeping gene was used as internal control for gene expression. Housekeeping 
genes are recognised as cellular maintenance gene that regulate basic cellular function. 
Therefore, we used GAPDH gene to normalise the RPS23 gene expression55. Thus, ensuring that 
the results obtained were not influence by individual genetic makeup. It is also important to 
mention that we performed the eQTL analysis with a low number of samples and most of the 
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rSNPs did not have all three genotypes. Thus, the low number of samples have an effect on the 
statistical power of the analysis. Nevertheless, as we have identified three potential rSNPs 
supported by strong evidence through DAE and eQTL approaches, further analysis should be 
conducted in order to understand the biological mechanisms involved in expression of the 
corresponding genes (ATG10, RPS23 and ATP6AP1L) and their relation to breast cancer. 
 c-Myc is a TF that integrates the cell cycle machinery with cell adhesion, cellular 
metabolism and apoptotic pathways56. c-Myc deregulation including gene amplification, 
transcriptional regulation, mRNA and protein stabilisation that correlate to loss of tumour 
suppressors and activation of oncogenic pathways, contributes to breast cancer development, 
progression and associated with poor outcomes57,58. 
 POL2 is known as a component of the general transcriptional mechanism and mediates 
the transcription process in cells. One study used POL2 binding data in order to predict 
translational regulation of anti-oestrogen resistance in breast cancer59. 
STAT3 is an important mediator of the transcriptional changes during tumorigenesis 
process and has been implicated in many types of cancers including breast cancer60.  
c-FOS has been reported to differently activate transcription of target genes and induce 
morphological changes in carcinoma61.  
Higher or lower binding affinity of these TFs could influence gene expression levels in an 
allele specific way, as observed with DAE ratios of the three genes in our study.  
Further analysis such as 3C (chromatin conformation capture) allows verification of 
interaction between one target site with another target site62–64. For example, the enhancer 
downstream of ATP6AP1L is contributing to its expression regulation, would it be able to come 
in contact with the promoter of ATP6AP1L. 4C (circularised chromatin conformation capture) 
allows one selected site to be used as a marker and the genome is screened for sequences that 
is in contact with the selected site65. As for 5C (carbon-copy chromatin conformation capture), it 
allows concurrent determination of interactions between multiple sequences66. 
There is very limited information on these three genes in the literature, particularly in 
relation to cancer. ATG10 gene is involved in autophagy and the ATG family genes are key 
regulators of this process. One study has reported an association between increased ATG10 
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expression and tissue invasion and lymphovascular metastasis, in colorectal cancer67,68. This is in 
opposition with our results, in which we see an association between higher expression and 
protection for breast cancer. 
RPS23 encodes the ribosomal protein S23, a component of the 40S subunit. This protein 
belongs to the S12P family of ribosomal proteins, is located in the cytoplasm and is crucial in the 
development of human diseases.  A study has reported over expression of RPS23 in early and 
advanced stages of colorectal adenocarcinomas69, supporting a possible role of this gene as an 
oncogene that is in accordance with what we observe in our study. 
ATP6AP1L also known as vacuolar H+-ATPase, is involved in controlling intracellular 
compartments in eukaryotic cells including intracellular membrane transport, pro-hormone 
processing and transport of neurotransmitters70. Several studies revealed an association of high 
activity of vacuolar H+-ATPase with breast cancer and regulation of vacuolar H+-ATPase as 
potential for cancer therapy71–73.  However, this is in opposition with our results, in which we see 
an association between higher expression and protection for breast cancer. 
Although several studies have investigated expression levels for these three genes in 
different types of cancer, their role in breast cancer predisposition and development has not 
been elucidated yet. Therefore, future studies on these genes might be of interest, in order to 
better understand the biological effects they may have in signalling pathways related to breast 
cancer.  
From our observation, we saw the possibility of a complex network of rSNPs regulating 
several genes in the 5q14.2 locus, which causes the signal in the GWAS SNP rs7707921 study. 
However, for now, we do not have the data to test these SNPs association with breast cancer 
risk.  
Our haplotypes analysis showed that combination of rSNPs (rs226198, rs6880209 and 
rs17247678) could possibly be regulating three genes (ATG10, RPS23 and ATP6AP1L) and lead to 
risk or protection to breast cancer. 
From our haplotype analysis, combination of Haplotype 1, which contained proxy GWAS 
SNP rs6888977 and rSNP rs226198 with Haplotype 9 that contained rSNP rs6880209, infer risk to 
breast cancer. This Haplotype 1 and Haplotype 9 combination has tSNPs rs10068160, rs7733620, 
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rs10044824 and rs226202 in Haplotype 1 and tSNP rs150934 in Haplotype 9. That correspond to 
over expression of RPS23 and under expression of ATG10 and ATP6AP1L. Contrary to Haplotype 
1 and Haplotype 9 combination, Haplotype 2 and Haplotype 10 combination infers protection to 
breast cancer. However, in order to verify this hypothesis, further association analysis on both 
Haplotype 1/Haplotype 9 and Haplotype2/Haplotype 10 combination with breast cancer should 
be conducted.  
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Chapter 6: Conclusion 
 
From our study, we were able to identify possible rSNPs that could be the causal variants 
of the risk-associated SNP rs7707921 for breast cancer. Three rSNPs (rs226198, rs6880209 and 
rs17247678) were identified as cis-acting regulators that seem to regulate three genes (ATG10, 
RPS23 and ATP6AP1L) in the 5q14.2 locus. Here, we propose model in which c-Myc and POL2 
binding to the common allele of rs226198 (A) and rs6880209 (C) lead to over expression of RPS23 
and under expression of ATG10, respectively. Meanwhile, STAT3 binding to the common allele of 
rs17247678 (G) and c-FOS binding to its vicinity lead to under expression of ATP6AP1L (Figure 
29). Risk to breast cancer could possibly be due to complex network of rSNPs regulation all three 
genes. Therefore, further analysis is needed to understand the underlying mechanism involved 
between the regulatory variants and the genes.  
Subsequently, these findings could contribute to better understanding of the biology for 
breast cancer as well as assist in the future development of cancer prevention and treatment 
therapies.  
 
 
  
  
Figure 29: Scheme representing the putative gene-regulation mechanism of the candidate rSNPs identified in this thesis. This 
putative gene-regulation mechanism confers risk to breast cancer associated with GWAS SNP rs7707921. c-Myc and POL2 binding 
to frequent allele rs226198 (A) and rs6880209 (C) lead to over expression of RPS23 and under expression of ATG10, respectively. 
Meanwhile STAT3 and c-FOS binding to frequent allele rs17247678 (G) and lead to under expression of ATP6AP1L. 
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Annex 
 
Annex 1: Score assigned by RegulomeDB according to the functional evidence. 
Table containing the SNP scores assigned by RegulomeDB according to the functional evidence 
in the database.  
 
 
  
Score Supporting Data 
Likely to affect binding and linked to expression of a gene target  
1a eQTL + TF binding + matched TF motif + matched DNase Footprint + DNase peak 
1b eQTL + TF binding + any motif + DNase Footprint + DNase peak 
1c eQTL + TF binding + matched TF motif + DNase peak 
1d eQTL + TF binding + any motif + DNase peak 
1e eQTL + TF binding + matched TF motif 
1f eQTL + TF binding / DNase peak 
Likely to affect binding  
2a TF binding + matched TF motif + matched DNase Footprint + DNase peak 
2b TF binding + any motif + DNase Footprint + DNase peak 
2c TF binding + matched TF motif + DNase peak 
Less likely to affect binding  
3a TF binding + any motif + DNase peak 
3b TF binding + matched TF motif 
Minimal binding evidence 
4 TF binding + DNase peak 
5 TF binding or DNase peak 
6 other 
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Annex 2: Oligonucleotide sequences designed for PCR and EMSA. 
In the table are represented the three selected SNPs to analyse. ATM 100 – ATM 103 are 
oligonucleotide sequences for PCR analysis meanwhile ATM 104 – ATM 107 are oligonucleotide 
sequences for EMSA analysis. Minor allele is shown first and the common allele is shown second. 
This table also show the sequences designed for both alleles for each SNP. 
 
Primer 
Name 
SNP Sequence 
ATM 100 rs2407153 (Forward) GCCCTTGCTTTAACTTTTGTATTG 
ATM 101 rs2407153 (Reverse) GATTCTTCTCCAGGGCTTCGTGAT 
ATM 102 rs226198 (Forward) AGGATGGGTGAGCTGTTGTG 
ATM 103 rs226198 (Reverse) CGGAGCTTCCTAGCAGTACG 
ATM 104 rs2406909 : T allele (Sense) ATTCCTCGGTTTGATTTCCATATTCCTAGTGTAAGT 
ATM 105 rs2406909 : T allele (Anti Sense) ACTTACACTAGGAATATGGAAATCAAACCGAGGAAT 
ATM 106 rs2406909 : C (Sense) ATTCCTCGGTTTGATTTCCACATTCCTAGTGTAAGT 
ATM 107 rs2406909 : C (Anti Sense) ACTTACACTAGGAATGTGGAAATCAAACCGAGGAAT 
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Annex 3: Labelling efficiency for Biotin Control DNA and annealed oligonucleotides. 
 
The figure below includes the dilution for each of the standard of the Procedures for Estimating 
Labelling Efficiency (A), as well as the labelling control of the kit and two different test 
oligonucleotides (B). ATM 104/105 correspond rs240609 T allele and ATM 106/107 correspond 
to rs240609 C allele.   
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Annex 4: DAE Mapping Analysis for tSNPs.  
DAE mapping analysis for ATP6AP1L at rs150934. 
The x-axis represent the genotypes meanwhile the y-axis represent the DAE ratio seen at the 
tSNP. Samples that are homozygous at the rSNP were observed to be located inside the dotted 
line as tSNP was expressed equally, hence, not causing the DAE effect. Meanwhile samples that 
are heterozygous at the rSNP were observed to be located above or below the dotted lines as 
tSNP was expressed unequally, hence, causing the DAE effect. [DAE ratio, log 2 (1.5) = 0.584]. 
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DAE mapping analysis for ATG10 at rs10044824. 
The x-axis represent the genotypes meanwhile the y-axis represent the DAE ratio seen at the 
tSNP. Samples that are homozygous at the rSNP were observed to be located inside the dotted 
line as tSNP was expressed equally, hence, not causing the DAE effect. Meanwhile samples that 
are heterozygous at the rSNP were observed to be located above or below the dotted lines as 
tSNP was expressed unequally, hence, causing the DAE effect. [DAE ratio, log 2 (1.5) = 0.584]. 
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DAE mapping analysis for ATG10 at rs7733620. 
The x-axis represent the genotypes meanwhile the y-axis represent the DAE ratio seen at the 
tSNP. Samples that are homozygous at the rSNP were observed to be located inside the dotted 
line as tSNP was expressed equally, hence, not causing the DAE effect. Meanwhile samples that 
are heterozygous at the rSNP were observed to be located above or below the dotted lines as 
tSNP was expressed unequally, hence, causing the DAE effect. [DAE ratio, log 2 (1.5) = 0.584]. 
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DAE mapping analysis for ATG10 at rs7733620. 
The x-axis represent the genotypes meanwhile the y-axis represent the DAE ratio seen at the 
tSNP. Samples that are homozygous at the rSNP were observed to be located inside the dotted 
line as tSNP was expressed equally, hence, not causing the DAE effect. Meanwhile samples that 
are heterozygous at the rSNP were observed to be located above or below the dotted lines as 
tSNP was expressed unequally, hence, causing the DAE effect. [DAE ratio, log 2 (1.5) = 0.584]. 
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DAE mapping analysis for RPS23 at rs226202. 
The x-axis represent the genotypes meanwhile the y-axis represent the DAE ratio seen at the 
tSNP. Samples that are homozygous at the rSNP were observed to be located inside the dotted 
line as tSNP was expressed equally, hence, not causing the DAE effect. Meanwhile samples that 
are heterozygous at the rSNP were observed to be located above or below the dotted lines as 
tSNP was expressed unequally, hence, causing the DAE effect. [DAE ratio, log 2 (1.5) = 0.584]. 
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Annex 5: ChIP-seq data for candidate rSNPs in the 5q14.2 locus. 
ChIP-seq data retrieved from CCLE database. In the table, the candidate rSNP identification, type 
of cell lines used in the experiments, total reads count and reads count per allele with their 
respective percentage are also included.  
 
  
Candidate 
rSNP 
Cell 
Line 
Protein 
Total 
Reads 
Reads % Reads % 
G Allele T Allele 
rs2407153 
(Region 2) 
MCF-7 CTCF 
1 0 0% 1 100% 
2 0 0% 2 100% 
2 0 0% 2 100% 
2 0 0% 2 100% 
1 0 0% 1 100% 
 
  
Candidate 
rSNP 
Cell 
Line 
Protein 
Total 
Reads 
Reads % Reads % 
C Allele G Allele 
rs10036937 
(Region 2) 
MCF-7 CTCF 
4 4 100% 0 0% 
17 17 100% 0 0% 
8 8 100% 0 0% 
1 1 100% 0 0% 
2 2 100% 0 0% 
11 11 100% 0 0% 
24 23 96% 1 4% 
11 11 100% 0 0% 
11 11 100% 0 0% 
12 12 100% 0 0% 
19 19 100% 0 0% 
6 6 100% 0 0% 
11 11 100% 0 0% 
HMF CTCF 
7 5 71% 2 29% 
23 14 61% 9 39% 
HMEC CTCF 
7 4 57% 3 43% 
3 2 67% 1 33% 
8 3 38% 5 63% 
7 4 57% 3 43% 
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Candidate 
rSNP 
Cell Line Protein 
Total 
Reads 
Reads % Reads % 
C Allele T Allele 
rs226198 
(Region 3) 
MCF-7 
c-Myc 
29 22 76% 7 24% 
20 18 90% 2 10% 
612 565 92% 42 7% 
104 89 86% 15 14% 
30 20 67% 10 33% 
20 17 85% 3 15% 
78 68 87% 10 13% 
38 30 79% 8 21% 
POL2 
2 1 50% 1 50% 
5 5 100% 0 0% 
18 11 61% 7 39% 
7 6 86% 1 14% 
7 6 86% 1 14% 
10 6 60% 4 40% 
MCF10A 
c-Myc 
35 23 66% 12 34% 
16 10 63% 6 38% 
5 2 40% 3 60% 
1 0 0% 1 100% 
POL2 
17 8 47% 9 53% 
28 13 46% 15 54% 
18 10 56% 8 44% 
34 17 50% 17 50% 
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Candidate 
rSNP 
Cell Line Protein 
Total 
Reads 
Reads % Reads % 
C Allele T Allele 
rs6880209 
(Region 3) 
MCF-7 
c-Myc 
41 13 32% 27 66% 
15 6 40% 9 60% 
227 39 17% 188 83% 
71 16 23% 55 77% 
11 3 27% 8 73% 
18 5 28% 13 72% 
58 8 14% 50 86% 
32 3 9% 29 91% 
POL2 
18 6 33% 12 67% 
39 14 36% 25 64% 
119 33 28% 86 72% 
105 23 22% 82 78% 
42 12 29% 30 71% 
40 13 33% 27 68% 
MCF10A 
c-Myc 
12 2 17% 10 83% 
19 6 32% 13 68% 
8 5 63% 3 38% 
8 1 13% 7 88% 
POL2 
42 21 50% 21 50% 
63 30 48% 33 52% 
41 18 44% 23 56% 
58 29 50% 29 50% 
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Candidate 
rSNP 
Cell Line Protein 
Total 
Reads 
Reads % Reads % 
G Allele A Allele 
rs17247678 
(Region 4) 
MCF10A 
c-FOS 
15 9 60% 6 40% 
3 1 33% 2 67% 
14 8 57% 6 43% 
7 3 43% 4 57% 
9 4 44% 5 56% 
5 1 20% 4 80% 
5 2 40% 3 60% 
6 2 33% 4 67% 
STAT3 
2 0 0% 2 100% 
15 3 20% 12 80% 
3 0 0% 3 100% 
9 3 33% 6 67% 
7 3 43% 4 57% 
9 3 33% 6 67% 
7 3 43% 4 57% 
20 7 35% 13 65% 
13 4 31% 9 69% 
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Annex 6: Total Expression of ATG10, RPS23 and ATP6AP1L genes for candidate rSNPs. 
The x-axis represent the candidate rSNP genotypes meanwhile y-axis represent log 2 (fold-change 
total expression for ATG10 gene.     
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The x-axis represent the candidate rSNP genotypes meanwhile y-axis represent log 2 (fold-change 
total expression for RPS23 gene.     
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The x-axis represent the candidate rSNP genotypes meanwhile y-axis represent log 2 (fold-change 
total expression for ATP6AP1L gene.     
 
